Compare CCRN & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCRN | HELP |
|---|---|---|
| Founded | 1986 | N/A |
| Country | United States | Canada |
| Employees | N/A | 50 |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 315.1M | 281.4M |
| IPO Year | 2001 | N/A |
| Metric | CCRN | HELP |
|---|---|---|
| Price | $9.50 | $4.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $14.15 | ★ $95.00 |
| AVG Volume (30 Days) | 547.2K | ★ 1.1M |
| Earning Date | 03-04-2026 | 07-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $816,484,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.93 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.43 | $4.41 |
| 52 Week High | $15.30 | $8.55 |
| Indicator | CCRN | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 53.65 | 35.50 |
| Support Level | $7.68 | $4.47 |
| Resistance Level | $10.28 | $4.95 |
| Average True Range (ATR) | 0.40 | 0.34 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 46.49 | 7.19 |
Cross Country Healthcare Inc is a healthcare workforce solutions company delivering an AI-powered digital platform and advisory services to help health systems manage their labor ecosystem. It operates through two reportable segments: Nursing and Allied Staffing, which generates maximum revenue and provides staffing, recruiting, total talent solutions, vendor neutral programs, managed service programs, education healthcare services, caregiver services to PACE programs and outsourcing services; and Physician Staffing, which provides licensed practitioners including certified registered nurse anesthetists, nurse practitioners and physician assistants on temporary assignments. The company recruits professionals nationally and places them with healthcare facilities across the United States.
Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.